CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis


Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Originally published April 20, 2021.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: